K-Bio has become a global production hub

Celltrion DongbangFTL selected as Pfizer's consignment manufacturer for Paxlovid

MSD's Lagevrio is co-developed with Hanmi, Ildong and Shionogi

Global supply of 5 vaccines, 3 antibody treatments, and 3 oral treatments in Korea

The Korean pharmaceutical bio industry has become a global coronavirus vaccine and treatment consignment production hub.

 

With the consignment production of coronavirus vaccines and antibody treatments in charge, the company will be in charge of consignment production of oral treatments for the supply of underdeveloped countries.

 

On the 17th, the MOHW announced that Celltrion and DongbangFTL were selected as generic producers of the oral corona treatment Paxlovid developed by Pfizer.

 

Celltrion produces finished products and DongbangFTL produces Nirmatrelvir.

 

The products produced here are supplied to 95 underdeveloped countries.

 

MPP, along with two Korean companies, selected a total of 35 companies from 12 countries around the world.

 

There are 19 in India, 5 in China, 1 in Bangladesh, Vietnam, Brazil, Dominican Republic, Mexico, Jordan, Israel, Serbia and Pakistan.

 

In January, International Pharmaceutical Patent Pool also selected three Korean companies as generics of the oral coronavirus treatment developed by MSD.

 

Hanmi Pharmaceutical was selected along with Celltrion and DongbangFTL.

 

Ildong Pharmaceutical is jointly developing another oral treatment candidate material "S-717622" with Shionogi of Japan.

 

Ildong Pharmaceutical plans to produce oral treatments with Shionogi and supply them globally as soon as the clinical trial is completed.

 

It is interpreted that the stable production capacity of Korean companies has been verified by the world over the fact that they have been selected as a producer of oral treatments one after another.

 

Korean pharmaceutical companies are being used as consignment production bases for COVID-19 vaccines and antibody treatments by multinational pharmaceutical companies.

 

In the case of COVID-19 vaccines, five domestic companies have decided to commission production of five global vaccines.

 

SK Bioscience has been producing AstraZeneca and Novavax vacine since last year.

 

Samsung Biologics has signed a contract with Moderna and is producing a coronavirus vaccine.

 

Although it has not yet begun full-scale supply, the Korus Pharm consortium can commission Russian vaccine Sputnik V, while Hanmi Pharmaceutical and Enzychem can commission ZyCoV-D developed by Indian pharmaceutical company Zydus Cadila.

 

In addition, Samsung Biologics is commissioned to produce AstraZeneca Evusheld and Eli Lilly's Bamlanivimab, which are corona antibody treatments.

 

Celltrion has produced and is supplying its own antibody treatment drug Regkirona globally.

 

At the end of last year, it was approved for use in Europe.

 

An official from the pharmaceutical industry said, "Korea has large-scale facilities for consignment production and has high reliability in quality.

 

With the Corona incident, the status of the Korean pharmaceutical bio industry will increase, and the value of the K-bio brand will also increase on the global stage in the future."